Please ensure Javascript is enabled for purposes of website accessibility

3 Biotech Stocks to Buy in March

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Our experts weigh in on why they like Vertex Pharmaceuticals, Neuralstem, and Intercept Pharmaceuticals.

"Our life is March weather, savage and serene in one hour." -- Ralph Waldo Emerson

Substitute "biotechs" for "our life" and you have the investing version of Emerson's quote. Depending on how binary events go, they can certainly become savage or serene quite quickly.

We asked our team of experts for their top biotech picks to watch this month. Read below to find out why they like Vertex Pharmaceuticals (VRTX 1.66%)Neuralstem (CUR), and Intercept Pharmaceuticals (ICPT -1.13%).

Brian Orelli: If you're looking for a biotech with upcoming catalysts, look no further than Vertex Pharmaceuticals. The company is developing serveral drugs for cystic fibrosis, and it expects clinical trial data and an expanded label this month, and there's potential for Food and Drug Administration approval for a separate drug combination soon.

Source: Vertex Pharmaceuticals.

Cystic fibrosis is caused by different mutations that need to be treated with different drugs. Vertex's Kalydeco is already approved to treat patients with the G551D and other gating mutations in patients age 6 or older, and it's up for approval to expand the indication to children as young as 2. Vertex should hear from the FDA about the incremental increase on or before March 17.

This month, Vertex also expects to release data from a phase 2 trial testing a combination of VX-661 and Kalydeco in patients with a different mutation called F508del. With a relatively small trial and seven different treatment groups, it might be hard to interpret how well the drug is really working. But management must think the data is good enough because Vertex has already started a phase 3 program with the combination.

VX-661 is actually a second-generation drug. The FDA is already reviewing Vertex's application to market the first-generation drug, lumacaftor, in combination with Kalydeco in patients with the F508del mutation. The agency is supposed to make a ruling on or before July 5, but considering the unmet need, we could get an early FDA approval, making Vertex a company investors will definitely want to keep an eye on.

Todd Campbell: One of the most exciting things about investing in biotech stocks is discovering companies that are working on what could truly be game-changing therapeutics.

One of those companies is Neuralstem, a clinical-stage small-cap biotech that is researching a stem cell treatments for ALS. This nervous-system affliction (also known as Lou Gehrig's Disease) can be devastating, but there are currently no FDA-approved treatments that target the disease directly. Neuralstem hopes to change that.

The company treated the final ALS patient in its NSI-566 phase 2 trial last summer, and results from that study are expected soon. This is unquestionably a binary event: If the midstage trial succeeded, then it could mark a major advance in patient treatment; if it failed, then shares will likely fall significantly. As a result, investors should approach this high-risk play with caution. In fact, it might be better to wait for the results before jumping in. Although something could later derail the drug in phase 3, a positive phase 2 result could mean this one is worth a little risk.

Dan CaplingerMy pick in the biotech realm is Intercept Pharmaceuticals, which has made a name for itself with its obeticholic acid treatment for liver disease. For more than a year now, excitement in the stock has run high, with early and midstage clinical trials suggesting possible treatment indications for primary biliary cirrhosis and nonalcoholic steatohepatitis, also known as NASH. The stock's most recent rise was sparked by the January announcement that Intercept had received breakthrough therapy status from the FDA for using obeticholic acid to treat NASH. With the incidence of NASH on the rise, new treatment options come at a premium.

Intercept has far to go before it can expect full FDA approval for its NASH treatment, with the company still planning a phase 3 trial. But with plans to submit a marketing application to U.S. and European regulators in the first half of this year for obeticholic acid to treat primary biliary cirrhosis, Intercept will have plenty of catalysts in the coming months to lift its shares back toward their 2014 highs. Add in the rise in mergers and acquisitions interest in the biotech space lately, and Intercept has even more promise to provide positive returns to shareholders in 2015 and beyond.

Brian OrelliDan Caplinger, and Todd Campbell have no position in any stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seneca Biopharma, Inc. Stock Quote
Seneca Biopharma, Inc.
CUR
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$298.83 (1.66%) $4.88
Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
ICPT
$16.66 (-1.13%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.